CClinicalTrials.gg
Enrolling by invitationNCT07866391Updated Oct 8, 2026

Vitamin D Status and Its Influencing Factors in Zhejiang Province: A Multicenter Cross-Sectional Study

An observational study in Vitamin D Deficiency, sponsored by First Affiliated Hospital of Zhejiang University. Enrolling by invitation at 2 sites in China. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by First Affiliated Hospital of Zhejiang University · Observational

Updated Oct 8, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10,000
Sex
All
01

Study summary

Vitamin D deficiency is a global public health problem, with an estimated 1 billion people affected worldwide, and large-scale systematic data for Zhejiang Province remain scarce. This is a multicenter, retrospective cross-sectional study. The objectives are to: (1) assess the distribution of serum 25-hydroxyvitamin D [25(OH)D] levels across regions, seasons, and demographic groups in Zhejiang Province and estimate the prevalence of vitamin D deficiency (\<20 ng/mL) and insufficiency (20-29 ng/mL); (2) identify and quantify key determinants of vitamin D status, including environmental exposures (ultraviolet radiation, green coverage), lifestyle (outdoor activity, sun protection), dietary vitamin D intake, and individual characteristics; and (3) provide scientific evidence for targeted intervention strategies, public health policy, and clinical guidelines in Zhejiang Province.

02

Conditions studied

  • Vitamin D Deficiency

Browse trials for

03

In context

Vitamin D Deficiency

773 studies on the registry are indexed under Vitamin D Deficiency; 61 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 138 across 183 observational studies indexed under Vitamin D Deficiency.

Browse Vitamin D Deficiency studies →

Lead sponsor

First Affiliated Hospital of Zhejiang University is the lead sponsor of 256 studies on the registry; 140 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population comprises individuals who underwent serum 25-hydroxyvitamin D [25(OH)D] measurement at multiple hospitals in Zhejiang Province in 2025. The population includes healthy individuals undergoing routine health checkups as well as patients with various chronic diseases (including chronic kidney disease, diabetes, and autoimmune diseases), spanning all age groups.

Inclusion criteria

  1. Patients who completed serum 25(OH)D testing at participating hospitals in this study.
  2. Able to understand the study and voluntarily sign the electronic informed consent form via the mobile mini-program.
  3. Able to complete the electronic questionnaire independently or with assistance from family members.

Exclusion criteria

Exclusion Criteria:

  1. Long-term use of medications known to affect vitamin D metabolism (e.g., certain antiepileptic drugs, glucocorticoids).
  2. Refusal to sign informed consent or complete the questionnaire; history of immunodeficiency or organ transplantation.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Zhejiang

    Patients who completed serum 25(OH)D measurement at participating hospitals in Zhejiang Province in 2025.

06

What researchers measure

Primary outcomes

  1. Serum 25-hydroxyvitamin D [25(OH)D] concentration

    Serum 25-hydroxyvitamin D \[25(OH)D\] concentration, expressed in ng/mL. Measured from existing clinical laboratory results at each participating hospital.

    Time frame: Time frame: Baseline (testing in 2025).

07

Study locations

2 sites
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Lishui Center Hospital
    Lishui, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866391
Lead sponsor
First Affiliated Hospital of Zhejiang University
Collaborators
Bioinformatics Society of Zhejiang Province
Responsible party
Sponsor
First posted
Oct 8, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion